Antidepressant use during pregnancy

References

• Rost K. Disability from depression: the public health challenge to primary care. Nord. J. Psychiatry63(1), 17–21 (2009).
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Current depression among adults: US, 2006 and 2008. MMWR Morb. Mortal. Wkly Rep.59(38), 1229–1235 (2010).
   PubMedGoogle Scholar
• Wisner KL, Zarin DA, Holmboe ES et al. Risk–benefit decision making for treatment of depression during pregnancy. Am. J. Psychiatry157, 1933–1940 (2000).
   PubMed Web of Science ®Google Scholar
• Burt CW, McCaig LF, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2005. Adv. Data388, 1–15 (2007).
   PubMedGoogle Scholar
• Finer L, Henshaw S. Disparities in rates of unintended pregnancy in the United States, 1194–2001. Perspect. Sex Reprod. Health38, 90–96 (2006).
   PubMed Web of Science ®Google Scholar
• Alwan S, Reefhuis J, Rasmussen SA, Friedman JM; National Birth Defects Prevention Study. Patterns of antidepressant medication use among pregnant women in a United States population. J. Clin. Pharm.51(2), 264–270 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen LS, Nonacs RM. Mood and anxiety disorders during pregnancy and postpartum. In: Review of Psychiatry (Volume 24). American Psychiatric Publishing Inc., VA, USA (2005).
   Google Scholar
• Cohen LS, Nonacs RM, Bailey JW, Viguera AC, Reminick AM. Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch. Womens Ment. Health7, 217–221 (2004).
   PubMedGoogle Scholar
• Tagle NM, Neal C, Glover V. Early stress translational research and prevention science network: fetal and neonatal experience on child and adolescent mental health. Antenatal maternal stress and long term effects on child neurodevelopment: how and why? J. Child Psychol. Psychiatry48, 245–261 (2007).
   PubMedGoogle Scholar
• Davis EP, Snidman N, Wadhwa PD, Glynn LM, Schetter CD, Sandman CA. Prenatal maternal anxiety and depression predict negative behavioral reactivity in infancy. Infancy6, 319–331 (2004).
   Web of Science ®Google Scholar
• Muckle G, Laflamme D, Gagnon J, Boucher O, Jacobson JL, Jacobson SW. Alcohol, smoking, and drug use among Inuit women of childbearing age during pregnancy and the risk to children. Alcohol Clin. Exp. Res.35(6), 1–11 (2011).
   PubMedGoogle Scholar
• Massey SH, Lieberman DZ, Reiss D, Leve LD, Shaw DS, Nelderhiser JM. Association of clinical characteristics and cessation of tobacco, alcohol, and illicit drug use during pregnancy. Am. J. Addict.20(2), 143–150 (2011).
   PubMed Web of Science ®Google Scholar
• Sadeh N, Javdani S, Sima Finy M, Verona E. Gender differences in emotional risk for self- and other-directed violence among externalizing adults. J. Consult. Clin. Psychol.79(1), 106–117 (2011).
   PubMed Web of Science ®Google Scholar
• Frieder A, Dunlop AL, Culpepper L, Bernstein PS. The clinical content of preconception care: women with psychiatric conditions. Am. J. Obstet. Gynecol.199(6 Suppl. 2), S328–S332 (2008).
   PubMed Web of Science ®Google Scholar
• Dayan J, Creveuil C, Helicoviez M et al. Role of anxiety and depression in the onset of spontaneous preterm labor. Am. J. Epidemiol.155, 293–301 (2002).
   PubMed Web of Science ®Google Scholar
• Orr S, James SA, Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm birth among African–American women in Baltimore, Maryland. Am. J. Epidemiol.156, 797–802 (2002).
   PubMed Web of Science ®Google Scholar
• Steer RA, Scholl TO, Hediger ML. Self reported depression and negative pregnancy outcomes. J. Clin. Epidemiol.45, 1093–1099 (1992).
   PubMed Web of Science ®Google Scholar
• Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight and intrauterine growth restriction. Arch. Gen. Psychiatry67(10), 1012–1024 (2010).
   PubMed Web of Science ®Google Scholar
• Davey HL, Tough SC, Adair CE, Benzies KM. Risk Factors for sub-clinical and major postpartum depression among a community cohort of Canadian women. Matern. Child Health J. DOI: 10.1007/s10995-008-0314-8 (2008) (Epub ahead of print).
   Google Scholar
• Misri S, Reebye P, Kendrick K. Internalizing behaviors in 4 year old children exposed in utero to psychotropic medications. Am. J. Psychiatry163, 1026–1032 (2006).
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Reebye P, Misri S et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch. Pediatr. Adolesc. Med.161, 22–29 (2007).
   PubMed Web of Science ®Google Scholar
• Halbreich U. the association between pregnancy processes, preterm delivery, low birth weight and postpartum depression-the need for interdisciplinary integration. Am. J. Obstet. Gynecol.193, 1312–1322 (2005).
   PubMed Web of Science ®Google Scholar
• Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Best Pract. Res. Clin. Obstet. Gynaecol.14, 839–854 (2000).
   PubMed Web of Science ®Google Scholar
• Brown S. Miscarriage and its associations. Semin. Reprod. Med.26, 391–400 (2008).
   PubMed Web of Science ®Google Scholar
• Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. Br. Med. J.299, 541–545 (1989).
   PubMed Web of Science ®Google Scholar
• McElhatton PR, Garbis HM, Elefant E. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European network of teratology information services. Reprod. Toxicol.10, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Pastuszak A, Schicht-Boschetto B, Zuber C et al. Pregnancy outcome following first-trimester exposure to fluoxetine. JAMA269(17), 2246–2248 (1993).
   PubMed Web of Science ®Google Scholar
• Hemels MEH, Einarson A, Koren G, Lanctot KL, Einarson TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann. Pharmacother.39, 803–809 (2005).
   PubMed Web of Science ®Google Scholar
• Einarson A, Choi J, Einarson T, Koren G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J. Obstet. Gynaecol. Can.3(5), 452–456 (2009).
   Google Scholar
• Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ182(10), 1031–1037 (2010).
   PubMed Web of Science ®Google Scholar
• Einarson A, Fatoye B, Sarkar M et al. Pregnancy outcome following getstational exposure to venlafaxine: a multicenter prospective controlled study. Am. J. Psych.158, 1728–1730 (2001).
   PubMed Web of Science ®Google Scholar
• Einarson A, Bonari L, Voyer-Lavigne S et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can. J. Psych.48, 106–110 (2003).
   Google Scholar
• Chun-Fai-Chan B, Koren G, Fayez I et al. Pregnancy outcomes of women exposed to bupropion during pregnancy: a prospective comparative study. Am. J. Ob. Gyn.192, 932–936 (2005).
   PubMed Web of Science ®Google Scholar
• Tuccori M, Testi A, Antonioli L. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonin/noradrenergic antidepressants during pregnancy. Clin. Ther.31(Pt 1), 1426–1453 (2009).
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod. Toxicol.22, 571–575 (2006).
   PubMed Web of Science ®Google Scholar
• Newport JD, Fisher A, Graybeal S, Stowe Z. Psychopharmacology during pregnancy and lactation. In: The Textbook of Psychopharmacology. Schatzberg AF, Nemeroff CB (Eds). American Psychiatric Publishing Inc., VA, USA, 1121 (2004).
   Google Scholar
• Kallen BAJ, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod. Toxicol.17, 255–261 (2003).
   PubMed Web of Science ®Google Scholar
• Kallen B, Olausson PO. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod. Toxicol.21, 221–222 (2006).
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am. J. Psychiatry153, 592–606 (1996).
   PubMed Web of Science ®Google Scholar
• Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol. Med.40, 1723–1733 (2010).
   PubMed Web of Science ®Google Scholar
• Chambers CD, Johnson KA, Dick LM, Felix RJ, Lyons Jones K. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med.335, 1010–1015 (1996).
   PubMed Web of Science ®Google Scholar
• Wu Wen S, Yang Q, Garner P et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am. J. Ob. Gyn.194, 961–966 (2006).
   PubMedGoogle Scholar
• Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol. Drug Saf.14, 823–827 (2005).
   PubMed Web of Science ®Google Scholar
• Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N. Engl. J. Med.356, 2675–2683 (2007).
   PubMed Web of Science ®Google Scholar
• Alwan SM, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin reuptake inhibitors in pregnancy and the risk of birth defects. N. Engl. J. Med.356, 2684–2692 (2007).
   PubMed Web of Science ®Google Scholar
• Diav Citrin O, Shechtman S, Weinbaum D. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reprod. Toxicol.20, 459 (2005).
   Google Scholar
• Wogelius P, Norgaard M, Gislum M. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology17(6), 701–704 (2006).
   PubMed Web of Science ®Google Scholar
• Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin. Epidemiol.2, 29–36 (2010).
   PubMedGoogle Scholar
• Einarson A, Pistelli A, DeSantis M. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am. J. Psychiatry165, 749–752 (2008).
   PubMed Web of Science ®Google Scholar
• Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin. Proc.84(1), 23–27 (2009).
   PubMed Web of Science ®Google Scholar
• Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Research Part A88, 159–170 (2010).
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ339, b3569 (2009).
   PubMed Web of Science ®Google Scholar
• Scialli AR. Paroxetine exposure during pregnancy and cardiac malformations. Birth Defects Res. A Clin. Mol. Teratol.88, 175–177 (2010).
   PubMedGoogle Scholar
• Einarson A, Choi J, Einarson TR, KorenG. Incidence of major malformations in infants following antidepressants exposure in pregnancy: results of a large prospective cohort study. Can. J. Psychiatry54(4), 242–246 (2009).
   PubMed Web of Science ®Google Scholar
• Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J. Clin. Psychopharmacol.27, 607–613 (2007).
   PubMed Web of Science ®Google Scholar
• Djulus J, Koren G, Einarson TR et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J. Clin. Psychiatry67(8), 1280–1284 (2006).
   PubMed Web of Science ®Google Scholar
• O’Brien L, Einarson TR, Sarkar M, Einarson A. Does paroxetine cause cardiac malformations? J. Obstet. Gynaecol. Can.30(8), 696–701 (2008).
   PubMedGoogle Scholar
• Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am. J. Psychiatry164, 1206–1213 (2007).
   PubMed Web of Science ®Google Scholar
• Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcome. Arch. Pediatr. Adolesc. Med.163(10), 949–954 (2009).
   PubMedGoogle Scholar
• Wisner KL, Sit DKY, Hanusa BH. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am. J. Psychiatry166, 557–566 (2009).
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry63, 898–906 (2006).
   PubMed Web of Science ®Google Scholar
• Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry159, 2055–2061 (2002).
   PubMed Web of Science ®Google Scholar
• Rampono J, Simmer K, Ilett KF et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry42, 95–100 (2009).
   PubMed Web of Science ®Google Scholar
• Casper RC, Fleisher BE, Lee-Ancajas JC et al. Follow up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr.142, 402–408 (2003).
   PubMed Web of Science ®Google Scholar
• Einarson A, Choi J, Einarson TR, Koren G. Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth. Depress. Anxiety27, 35–38 (2010).
   PubMed Web of Science ®Google Scholar
• Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch. Pediatr. Adolesc. Med.156, 1129–1132 (2002).
   PubMed Web of Science ®Google Scholar
• Malm H, Klaukka T, Neuvonen PJ. Risk associated with selective serotonin reuptake inhibitors in pregnancy. Obstet. Gynecol.106(6), 1289–1296 (2005).
   PubMed Web of Science ®Google Scholar
• Hernandez Diaz S, Van Marter LJ, Weler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of newborn. Pediatrics120, e272–e282 (2007).
   Google Scholar
• Perreault T. Persistent pulmonary hypertension of the newborn. Paediatr. Respir. Rev.7, S175–S176 (2006).
   PubMedGoogle Scholar
• Chambers CD, Hernandez-Diaz S, Van Mater LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med.354, 579–587 (2006).
   PubMed Web of Science ®Google Scholar
• Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf.17, 801–806 (2008).
   PubMed Web of Science ®Google Scholar
• Andrade SE, McPhillips H, Loren D et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf.18, 246–252 (2009).
   PubMed Web of Science ®Google Scholar
• Wilson KL, Zelig CM, Harvey JP et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am. J. Perinatol.28(1), 19–24 (2010).
   PubMedGoogle Scholar
• Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. Literature review and implications for clinical applications. JAMA293, 2372–2383 (2005).
   PubMed Web of Science ®Google Scholar
• Ferreira E, Canceller AM, Agogue C et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm infants. Pediatrics119(1), 52–59 (2007).
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Wisner KL, Stewart DE et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen. Hosp. Psychiatry31(5), 403–413 (2009).
   PubMed Web of Science ®Google Scholar
• Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch. Pediatr. Adolesc. Med.160(2), 173–176 (2006).
   PubMed Web of Science ®Google Scholar
• Sanz EJ, De-La-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet365, 482–487 (2005).
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Misri S, Fitzgerald CE et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J. Clin. Psychiatry65, 230–237 (2004).
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br. J. Psychiatry192, 338–343 (2008).
   PubMed Web of Science ®Google Scholar
• Boucher N, Koren G, Beaulac-Baillargeon L. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther. Drug Monit.139(3), 404–409 (2009).
   Google Scholar
• Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Actaeon. Psychiatr. Scand.121, 471–479 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen LS, Wang B, Nonacs R, Viguera AC, Lemon EL, Freeman MP. Treatment of mood disorders during pregnancy and postpartum. Psychiatr. Clin. North. Am.33(2), 273–293 (2010).
   PubMed Web of Science ®Google Scholar
• Koren G, Boucher N. Adverse effects in neonates exposed to SSRI and SNRI in late gestation. Can. J. Clin. Pharmacol.16(1), e66–e67 (2009).
   PubMedGoogle Scholar
• Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin. Pharmacol. Ther.86(6), 672–677 (2009).
   PubMed Web of Science ®Google Scholar
• Borue X, Chen J, Condron BG. Developmental effects of SSRI’s: lessons learned from animal studies. Int. J. Dev. Neurosci.25(6), 341–347 (2007).
   PubMedGoogle Scholar
• Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol. Sci.31(2), 60–65 (2009).
   PubMedGoogle Scholar
• Nulman I, Rovet J, Stewart DE. Neurodevelopment of children exposed in utero to antidepressants drugs. N. Engl. J. Med.336, 258–262 (1997).
   PubMed Web of Science ®Google Scholar
• Nulman I, Rovet J, Stewart DE. Child development following exposure to tricyclics antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry159, 1889–1895 (2002).
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics125, e600–e608 (2010).
   PubMed Web of Science ®Google Scholar
• Weissman MM, Wickramaratne P, Nomura Y et al. Offspring of depressed parents: 20 years later. Am. J. Psychiatry163, 1001–1008 (2006).
   PubMed Web of Science ®Google Scholar
• Sutter-Dallay AL, Murray L, Dequae-Merchadou L et al. A prospective longitudinal study of the impact of early vs. chronic maternal depressive symptoms on child development. Eur. Psychiatry DOI: 10.1016/j.eurpsy.2010.05.004 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Pearlstein T, Howard M, Salisbury A, Zlotnic C. Postpartum depression. Am. J. Obstet. Gynecol.200(4), 357–364 (2009).
   PubMed Web of Science ®Google Scholar
• Tompson MC, Pierre CB, McKowen JW, Chan PT, Freed RD. Maternal depression, maternal expressed emotion, and youth psychopathology. J. Abnorm. Child Psychol.38(1), 105–117 (2010).
   PubMed Web of Science ®Google Scholar
• Kouros CD, Garber J. Dynamic associations between maternal depressive symptoms and adolescents’ depressive and externalizing symptoms. J. Abnorm. Child Psychol.38(8), 1069–1081 (2010).
   PubMed Web of Science ®Google Scholar